Trial · NCT07910006
Multimodal Assessment of NMES Effects on Respiratory and Peripheral Muscles in COPD
NCT07910006, Not applicable, Recruiting, Universitas Padjadjaran
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multimodal Assessment of NMES Effects on Respiratory and Peripheral Muscles in COPD. Trials, record NCT07910006. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910006
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multimodal Assessment of NMES Effects on Respiratory and Peripheral Muscles in COPD
- NCT number
- NCT07910006
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Universitas Padjadjaran
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Respiratory Muscle Dysfunction, Muscle Weakness
- Interventions
- Neuromuscular Electric Stimulation, Exercise
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diaphragm Excursion (DE) | Baseline (Week 0) and post-intervention (Week 8) | Measured via B-mode or M-mode transabdominal ultrasound during quiet and deep breathing to evaluate the distance the diaphragm travels vertically. A higher excursion value indicates better diaphragmatic mobility. |
| Primary | Diaphragm Thickening Fraction (TF) | Baseline (Week 0) and post-intervention (Week 8) | Calculated using the formula: \[(Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration\] x 100%. Measured via high-frequency linear ultrasound at the zone of apposition to assess diaphragmatic contractile function. |
| Secondary | Change in Plasma Interleukin-6 (IL-6) Levels | Baseline (Week 0) and post-intervention (Week 8) | Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate systemic inflammatory profiles. Decreased levels indicate a reduction in systemic inflammation. |
| Secondary | Change in Plasma Insulin-like Growth Factor-1 (IGF-1) Levels | Baseline (Week 0) and post-intervention (Week 8) | Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate muscle anabolic activity and systemic growth factor response. Increased levels indicate an improved anabolic state. |
| Other | Six-Minute Walk Test (6MWT) Distance | Baseline (Week 0) and post-intervention (Week 8) | Measured by the total distance in meters that a participant can walk quickly on a flat, hard surface in a period of 6 minutes. It evaluates functional exercise capacity. |
| Other | Modified Medical Research Council (mMRC) Dyspnea Scale | Baseline (Week 0) and post-intervention (Week 8) | A questionnaire used to rate the baseline dyspnea (breathlessness) on a scale from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house). Lower scores indicate less respiratory disability. |
| Other | COPD Assessment Test (CAT) Score | Baseline (Week 0) and post-intervention (Week 8) | An 8-item questionnaire measuring the health status impairment in COPD patients. Scores range from 0 to 40, where higher scores signify a worse health status and severe impact of COPD on the patient's life. |
| Other | Modified Borg Scale (MBS) for Dyspnea | Baseline (Week 0) and post-intervention (Week 8) | A categorical scale ranging from 0 (no breathlessness at all) to 10 (maximal breathlessness) used to assess the patient's perceived level of shortness of breath during functional activity or rest. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910006
GET https://conductscience.org/api/trials/v1/NCT07910006/registered